Welcome to The Five Under 5, your go-to roundup of the top 5 videos of the week.

These short videos are designed for busy oncologists to view on the go, and feature expert insights on breaking news, regulatory updates, practice-changing data shared at medical meetings, and other key topics in the realm of oncology.

Here’s what you may have missed:

Adjuvant Atezolizumab in Patients With MIBC Who Were ctDNA+ After Initial Testing: With Joaquim Bellmunt, MD, PhD

Joaquim Bellmunt, MD, PhD, the director of the Bladder Cancer Center and a senior physician at Dana-Farber Cancer Institute, as well as an associate professor of medicine at Harvard Medical School, discussed efficacy data from subgroup analyses, as well as safety results, from the phase 3 IMvigor011 trial (NCT04660344) of circulating tumor DNA (ctDNA)–guided adjuvant atezolizumab (Tecentriq) in patients with muscle-invasive bladder cancer (MIBC).

Clinical Considerations Surrounding the Diagnosis of LEMS in Patients With Lung Cancer: With Ticiana Leal, MD

Ticiana Leal, MD, a professor and director of the Thoracic Medical Oncology Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine, as well as medical director of the Clinical Trials Office at Winship Cancer Institute, outlined key considerations for medical oncologists in recognizing and diagnosing Lambert-Eaton myasthenic syndrome (LEMS), particularly in the context of small cell lung cancer (SCLC) and, in rarer cases, non–small cell lung cancer (NSCLC).

Updated Efficacy Data With Tovorafenib in R/R Pediatric Low Grade Glioma: With Cassie Kline, MD, MAS

Cassie Kline, MD, MAS, an attending physician and director of clinical research in the Department of Neuro-Oncology at the Children's Hospital of Philadelphia, shared updated results from the ongoing phase 2 FIREFLY-1 study (NCT04775485) evaluating tovorafenib (Ojemda) in relapsed/refractory pediatric low-grade glioma (pLGG). Previous results from FIREFLY-1 supported the FDA approval of tovorafenib for recurrent BRAF-altered pLGG in April 2024. The updated data, encompassing approximately 36 months of follow-up, were presented at the 2025 SNO Annual Meeting.

Efficacy of KRd Maintenance Therapy Post-ASCT in Multiple Myeloma: With Andrzej Jakubowiak, MD, PhD

Andrzej Jakubowiak, MD, PhD, a professor of medicine and the director of the Myeloma Program at University of Chicago Medicine, discussed the notable efficacy data from the phase 3 ATLAS study (NCT02659293) of carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (KRd) vs lenalidomide maintenance alone for the treatment of patients with multiple myeloma who have already received autologous stem cell transplantation (ASCT).

Role of Pharmacists in Treatment Planning and Management in CML: With Jose Tinajero, PharmD, BCOP

Jose Tinajero, PharmD, BCOP, a bone marrow transplant and hematology clinical pharmacist at City of Hope, outlined the essential role of the oncology pharmacist in the management of chronic myeloid leukemia (CML).

As treatment has evolved from first-generation TKIs to multiple second- and third-generation options and, more recently, allosteric inhibition, pharmacists have become increasingly integral to treatment planning, toxicity management, and patient adherence, he said.